Solaxa is a biopharmaceutical company developing novel and reformulated drugs that target ion channels to restore nerve function in patients with rare neurodegenerative diseases and nerve injuries. The company has demonstrated treatment responses in nine different ataxias, supported by extensive clinical studies and a robust patent portfolio.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with rare neurodegenerative diseases and nerve injuries often experience impaired nerve function, leading to debilitating symptoms and reduced quality of life. Current treatment options may be limited or ineffective in restoring proper nerve function in these conditions.
Solution
Solaxa is developing novel and reformulated drugs that target ion channels to restore nerve function in patients with rare neurodegenerative diseases and nerve injuries. The company's approach focuses on modulating ion channel activity to improve nerve signaling and function. Clinical studies have demonstrated treatment responses in multiple ataxias, suggesting the potential of Solaxa's drugs to address unmet needs in these patient populations. The company's therapeutic pipeline is supported by an intellectual property portfolio covering its drug candidates and methods of use.
Target Audience
The primary target audience includes patients suffering from rare neurodegenerative diseases and nerve injuries, as well as the physicians who treat these conditions.
Features
- Novel and reformulated drugs targeting ion channels
- Demonstrated treatment responses in nine different ataxias
- Extensive clinical studies in cerebellar ataxia patients
- Robust patent portfolio with issued and pending patents in the US, EU, and Canada